These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 33218898)

  • 1. Pyrrolo[2,3-b]pyridine-3-one derivatives as novel fibroblast growth factor receptor 4 inhibitors for the treatment of hepatocellular carcinoma.
    Jin Q; Zhang D; Gao M; Jiang C; Zhang J
    Bioorg Med Chem; 2021 Jan; 29():115862. PubMed ID: 33218898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
    Hagel M; Miduturu C; Sheets M; Rubin N; Weng W; Stransky N; Bifulco N; Kim JL; Hodous B; Brooijmans N; Shutes A; Winter C; Lengauer C; Kohl NE; Guzi T
    Cancer Discov; 2015 Apr; 5(4):424-37. PubMed ID: 25776529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and biological evaluation of quinazoline derivatives as potent and selective FGFR4 inhibitors.
    Pan C; Nie W; Wang J; Du J; Pan Z; Gao J; Lu Y; Che J; Zhu H; Dai H; Chen B; He Q; Dong X
    Eur J Med Chem; 2021 Dec; 225():113794. PubMed ID: 34488024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of 2,6-Naphthyridine Analogues as Selective FGFR4 Inhibitors for Hepatocellular Carcinoma.
    Oh H; Kim J; Jung SH; Ha TH; Ahn YG; Nam G; Moon K; Singh P; Kim IS
    J Med Chem; 2024 May; 67(10):8445-8459. PubMed ID: 38706130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer.
    Chen X; Liu Y; Zhang L; Chen D; Dong Z; Zhao C; Liu Z; Xia Q; Wu J; Chen Y; Zheng X; Cai Y
    Eur J Med Chem; 2021 Mar; 214():113219. PubMed ID: 33618175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 6-Amino-2,4,5-trimethylpyridin-3-ol and 2-amino-4,6-dimethylpyrimidin-5-ol derivatives as selective fibroblast growth factor receptor 4 inhibitors: design, synthesis, molecular docking, and anti-hepatocellular carcinoma efficacy evaluation.
    Chaudhary CL; Lim D; Chaudhary P; Guragain D; Awasthi BP; Park HD; Kim JA; Jeong BS
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):844-856. PubMed ID: 35296193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, Synthesis, and Biological Evaluation of 5-Formyl-pyrrolo[3,2-
    Yang F; Chen X; Song X; Ortega R; Lin X; Deng W; Guo J; Tu Z; Patterson AV; Smaill JB; Chen Y; Lu X
    J Med Chem; 2022 Nov; 65(21):14809-14831. PubMed ID: 36278929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of novel FGFR4 inhibitors through a build-up fragment strategy.
    Kim J; Im CG; Oh K; Lee JM; Al-Rubaye F; Min KH
    J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2343350. PubMed ID: 38655602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
    Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W
    Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and anticancer evaluation of arylurea derivatives as potent and selective type II irreversible covalent FGFR4 inhibitors.
    Wang M; Lan L; Wang YW; Zhang JY; Shi L; Sun LP
    Bioorg Med Chem; 2023 May; 87():117298. PubMed ID: 37196426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4.
    Fairhurst RA; Knoepfel T; Buschmann N; Leblanc C; Mah R; Todorov M; Nimsgern P; Ripoche S; Niklaus M; Warin N; Luu VH; Madoerin M; Wirth J; Graus-Porta D; Weiss A; Kiffe M; Wartmann M; Kinyamu-Akunda J; Sterker D; Stamm C; Adler F; Buhles A; Schadt H; Couttet P; Blank J; Galuba I; Trappe J; Voshol J; Ostermann N; Zou C; Berghausen J; Del Rio Espinola A; Jahnke W; Furet P
    J Med Chem; 2020 Nov; 63(21):12542-12573. PubMed ID: 32930584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells.
    Sbenati RM; Zaraei SO; El-Gamal MI; Anbar HS; Tarazi H; Zoghbor MM; Mohamood NA; Khakpour MM; Zaher DM; Omar HA; Alach NN; Shehata MK; El-Gamal R
    Eur J Med Chem; 2021 Jan; 210():113081. PubMed ID: 33310290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors.
    Li X; Guise CP; Taghipouran R; Yosaatmadja Y; Ashoorzadeh A; Paik WK; Squire CJ; Jiang S; Luo J; Xu Y; Tu ZC; Lu X; Ren X; Patterson AV; Smaill JB; Ding K
    Eur J Med Chem; 2017 Jul; 135():531-543. PubMed ID: 28521156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, Synthesis, and Biological Evaluation of 2-Formyl Tetrahydronaphthyridine Urea Derivatives as New Selective Covalently Reversible FGFR4 Inhibitors.
    Zhang Z; Li J; Chen H; Huang J; Song X; Tu ZC; Zhang Z; Peng L; Zhou Y; Ding K
    J Med Chem; 2022 Feb; 65(4):3249-3265. PubMed ID: 35119278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects.
    Lu X; Chen H; Patterson AV; Smaill JB; Ding K
    J Med Chem; 2019 Mar; 62(6):2905-2915. PubMed ID: 30403487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, biological evaluation and molecular modeling of novel 1H-pyrrolo[2,3-b]pyridine derivatives as potential anti-tumor agents.
    Wang R; Chen Y; Yang B; Yu S; Zhao X; Zhang C; Hao C; Zhao D; Cheng M
    Bioorg Chem; 2020 Jan; 94():103474. PubMed ID: 31859010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 7H-pyrrolo[2,3-d]pyridine derivatives as potent FAK inhibitors: Design, synthesis, biological evaluation and molecular docking study.
    Wang R; Zhao X; Yu S; Chen Y; Cui H; Wu T; Hao C; Zhao D; Cheng M
    Bioorg Chem; 2020 Sep; 102():104092. PubMed ID: 32707280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-cancer effects of 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives on hepatocellular carcinoma harboring FGFR4 activation.
    Nam Y; Shin I; Kim Y; Ryu S; Kim N; Ju E; Sim T
    Neoplasia; 2022 Jan; 24(1):34-49. PubMed ID: 34864570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma.
    Zhai S; Zhang H; Chen R; Wu J; Ai D; Tao S; Cai Y; Zhang JQ; Wang L
    Eur J Med Chem; 2021 Dec; 225():113824. PubMed ID: 34509167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of novel pyrrolo[2,3-b]pyridine derivatives targeting
    Abdel-Maksoud MS; Ali EMH; Ammar UM; Mersal KI; Yoo KH; Oh CH
    Bioorg Med Chem; 2020 Jun; 28(11):115493. PubMed ID: 32340792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.